Holen Sie sich die Stockscreener-App
5.438
1.59%
0.078
Schlusskurs vom Vortag:
$5.36
Offen:
$5.35
24-Stunden-Volumen:
322.84K
Relative Volume:
0.59
Marktkapitalisierung:
$295.52M
Einnahmen:
$163.78M
Nettoeinkommen (Verlust:
$25.88M
KGV:
2.3956
EPS:
2.27
Netto-Cashflow:
$-28.66M
1W Leistung:
-12.46%
1M Leistung:
-28.92%
6M Leistung:
-35.49%
1J Leistung:
-18.85%
1-Tages-Spanne:
$5.19
$5.49
1-Wochen-Bereich:
$5.19
$6.1499
52-Wochen-Spanne:
$5.19
$11.72
Voyager Therapeutics Inc Stock (VYGR) Company Profile
Firmenname
Voyager Therapeutics Inc
Sektor
Branche
Telefon
857-259-5340
Adresse
75 HAYDEN AVENUE, LEXINGTON, MA
Vergleichen Sie VYGR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| VYGR | 5.445 | 295.52M | 163.78M | 25.88M | -28.66M | 2.27 |
| VRTX | 450.67 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.27 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.22 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.29 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.27 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-05-10 | Eingeleitet | Truist | Buy |
| 2023-03-10 | Eingeleitet | Oppenheimer | Outperform |
| 2021-10-07 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2021-02-03 | Herabstufung | BTIG Research | Buy → Neutral |
| 2021-02-03 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-24 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2020-12-23 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-11-10 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2020-11-10 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-03-19 | Eingeleitet | The Benchmark Company | Buy |
| 2020-02-06 | Eingeleitet | Oppenheimer | Outperform |
| 2018-11-15 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-09-10 | Fortgesetzt | BTIG Research | Buy |
| 2018-09-10 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-06-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-12 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2018-03-12 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-02-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2017-11-28 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-10-31 | Eingeleitet | Robert W. Baird | Outperform |
| 2017-10-27 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-10-23 | Bestätigt | Stifel | Buy |
| 2017-10-12 | Eingeleitet | Raymond James | Outperform |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-07-28 | Fortgesetzt | Stifel | Buy |
Alle ansehen
Voyager Therapeutics Inc Aktie (VYGR) Neueste Nachrichten
Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease - GlobeNewswire
Voyager's New Alzheimer's Gene Therapy Shows 73% Tau Reduction in Key Study | VYGR Stock News - StockTitan
Voyager Therapeutics’ TRACER Platform Targets CNS Market: Here’s Why I’m Neutral (VYGR) - Seeking Alpha
StockNews.com Upgrades Voyager Therapeutics (NASDAQ:VYGR) to "Buy" - MarketBeat
FY2024 Earnings Forecast for VYGR Issued By HC Wainwright - MarketBeat
Voyager Therapeutics’ (VYGR) Buy Rating Reiterated at Canaccord Genuity Group - Defense World
Voyager Therapeutics’ (VYGR) Buy Rating Reiterated at HC Wainwright - Defense World
When the Price of (VYGR) Talks, People Listen - Stock Traders Daily
Voyager Therapeutics stock hits 52-week low at $5.71 - Investing.com India
EcoR1 Capital, LLC Increases Stake in Voyager Therapeutics Inc - GuruFocus.com
Leerink Partnrs Has Negative Outlook of VYGR FY2024 Earnings - MarketBeat
Voyager Therapeutics' (VYGR) Buy Rating Reiterated at Canaccord Genuity Group - MarketBeat
Voyager Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
Voyager Therapeutics (NASDAQ:VYGR) Earns Buy Rating from HC Wainwright - MarketBeat
Declining Stock and Decent Financials: Is The Market Wrong About Voyager Therapeutics, Inc. (NASDAQ:VYGR)? - Yahoo Finance
Earnings call: Voyager Therapeutics focuses on neurological therapies By Investing.com - Investing.com Canada
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q3 2024 Earnings Call Transcript - Insider Monkey
Voyager Therapeutics: Q3 Earnings Snapshot - Darien Times
Voyager Therapeutics Inc earnings beat by $0.29, revenue topped estimates - Investing.com Australia
Voyager Therapeutics Inc (VYGR) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... - Yahoo Finance
Voyager Therapeutics Reports Strong Q3 2024 Progress - TipRanks
Voyager Therapeutics Inc (VYGR) Q3 2024 Earnings: Revenue Soars to $24.63M, EPS Loss of $0.16 Beats Estimates - GuruFocus.com
Voyager Therapeutics (VYGR) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Voyager Reports Third Quarter 2024 Financial and Operating Results - GlobeNewswire
Voyager Therapeutics Revenue Soars 435% in Q3, Secures $15M Novartis Deal | VYGR Stock News - StockTitan
Voyager Therapeutics Inc (VYGR) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... By GuruFocus - Investing.com Canada
Voyager Therapeutics (NASDAQ:VYGR) Cut to Hold at StockNews.com - MarketBeat
Gene Therapy Market to Grow by USD 6.74 Billion from 2024-2028, as Rise in Special Drug Designations Drives Demand with AI-Powered Market EvolutionTechnavio - The Malaysian Reserve
Voyager Therapeutics (VYGR) to Release Quarterly Earnings on Tuesday - MarketBeat
Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences - The Manila Times
Voyager Therapeutics to Present at 4 Major Healthcare Investor Conferences in November | VYGR Stock News - StockTitan
Voyager Therapeutics Announces Third Quarter 2024 Conference Call and Webcast - GlobeNewswire
VYGRVoyager Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Voyager Therapeutics (VYGR) to Report Q3 2024 Earnings on November 12 | VYGR Stock News - StockTitan
Learn to Evaluate (VYGR) using the Charts - Stock Traders Daily
Strength Seen in Voyager Therapeutics (VYGR): Can Its 17.5% Jump Turn into More Strength? - MSN
Voyager Therapeutics (NASDAQ:VYGR) Rating Increased to Buy at StockNews.com - MarketBeat
Voyager Therapeutics (VYGR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Canada Finance
Brokerages Set Voyager Therapeutics, Inc. (NASDAQ:VYGR) PT at $17.43 - MarketBeat
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Rating of “Buy” from Analysts - Defense World
Voyager Therapeutics (NASDAQ:VYGR) Stock Rating Lowered by StockNews.com - Defense World
StockNews.com Lowers Voyager Therapeutics (NASDAQ:VYGR) to Hold - MarketBeat
How to Take Advantage of moves in (VYGR) - Stock Traders Daily
HC Wainwright Reaffirms Buy Rating for Voyager Therapeutics (NASDAQ:VYGR) - MarketBeat
Viral Vectors-Based Gene Therapy for Non-Human Primates Market - openPR
Neurologic Disorders Therapeutics Strategic Business Report - GlobeNewswire
Equities Analysts Offer Predictions for VYGR Q3 Earnings - MarketBeat
Voyager Therapeutics (NASDAQ:VYGR) Rating Increased to Strong-Buy at Leerink Partnrs - Defense World
Voyager Therapeutics (NASDAQ:VYGR) Upgraded to "Strong-Buy" by Leerink Partnrs - MarketBeat
Finanzdaten der Voyager Therapeutics Inc-Aktie (VYGR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):